The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia
Open accessAbstract
Mouse bone marrow cells transduced with retroviral vectors encoding either of two oncogenic Bcr-Abl isoforms (p210 Bcr-Abl and p185 Bcr-Abl ) induce B cell lympholeukemias when transplanted into lethally irradiated mice. If the activity of the Arf tumor suppressor is compromised, these donor cells initiate a much more highly aggressive and rapidly fatal disease. When mouse bone marrow cells expressing Bcr-Abl are placed in short-term cultures selectively designed to support the outgrowth of pre-B cells, only those lacking one or two Arf alleles can initiate lympholeukemias when inoculated into immunocompetent, syngeneic recipient mice. Although the ABL kinase inhibitor imatinib mesylate (Gleevec) provides highly effective treatment for BCR-ABL-positive chronic myelogenous leukemia, it has proven far less efficacious in the treatment of BCR-ABL-positive acute lymphoblastic leukemias (ALLs), many of which sustain deletions of the INK4A-ARF ( CDKN2A ) tumor suppressor locus. Mice receiving Arf −/− or Arf +/− p210 Bcr-Abl -positive pre-B cells do not achieve remission when maintained on high doses of oral imatinib therapy and rapidly succumb to lympholeukemia. Although cells expressing the Bcr-Abl kinase can proliferate in the absence of IL-7, they remain responsive to this cytokine, which can reduce their sensitivity to imatinib. Treatment of Arf −/− , p210 Bcr-Abl -positive pre-B cells with imatinib together with an inhibitor of JAK kinases abrogates this resistance, suggesting that this combination may prove beneficial in the treatment of BCR-ABL-positive acute lymphoblastic leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Self-citationJacobs, J. J. L., Kieboom, K., Marino, S., DePinho, R. A., & van Lohuizen, M. (1999) · Nature · doi:10.1038/16476 · Cited by 1,580
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Self-citationMyc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
Self-citationDisruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819
Self-citation
Research works printed but not linked: 29
- P. Nowell, D. Hungerford J. Natl. Cancer Inst 25, 85–109 (1960).
- 10.1016/0092-8674(84)90077-1 · DOI · Paper page
- 10.1126/science.3541203 · DOI · Paper page
- 10.1038/325635a0 · DOI
- 10.1038/283826a0 · DOI · Paper page
- 10.1182/blood-2004-08-3097 · DOI · Paper page
- 10.1016/S1535-6108(02)00096-X · DOI · Paper page
- 10.1126/science.1099480 · DOI · Paper page
- N. P. Shah Hematology: The American Society of Hematology Education Program Book (Am. Soc. Hematol., Washington, DC), pp. 183–187 (2005).
- 10.1200/JCO.2005.05.047 · DOI · Paper page
- 10.1038/sj.leu.2403324 · DOI
- 10.1038/sj.leu.2403714 · doi:10.1038/sj.leu.2403714
- 10.1101/gad.12.15.2434 · DOI · Paper page
- 10.1038/25870 · DOI · Paper page
- 10.1073/pnas.95.22.13194 · DOI
- 10.1016/j.cell.2004.08.005 · DOI · Paper page
- 10.1101/gad.13.20.2670 · DOI · Paper page
- 10.1101/gad.13.20.2678 · DOI · Paper page
- 10.1016/0076-6879(87)50085-4 · DOI
- 10.1073/pnas.171217498 · DOI
- 10.1073/pnas.84.18.6558 · DOI
- 10.1089/hyb.2004.23.293 · DOI
- 10.1038/ng1343 · DOI · Paper page
- 10.1182/blood.V98.9.2808 · DOI
- N. Jena, M. Deng, E. Sicinska, P. Sicinski, G. Q. Daley Cancer Res 62, 535–541 (2002).
- 10.1016/S0960-9822(00)00002-6 · DOI · Paper page
- 10.1073/pnas.052484199 · DOI
- 10.1089/hyb.1994.13.37 · DOI
- 10.4161/cc.4.11.2174 · DOI
Cited by
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y.-L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403088 · Cited by 1,377
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 714
Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo
Zhao, C., Blum, J., Chen, A., Kwon, H. Y., Jung, S. H., Cook, J. M., Lagoo, A., & Reya, T. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.003 · Cited by 592
Metadata
- Authors
- Williams, R. T., Roussel, M. F., & Sherr, C. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-04-25
- Volume
- 103
- Issue
- 17
- Pages
- 6688-6693
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2147270774
- Cited by
- 193
- References
- 6
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1073/pnas.0602030103
- The paper
- Williams, R. T., Roussel, M. F., & Sherr, C. J. (2006). Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0602030103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.